157 related articles for article (PubMed ID: 31144617)
1. NRG1 is a critical regulator of differentiation in TP63-driven squamous cell carcinoma.
Hegde GV; de la Cruz C; Giltnane JM; Crocker L; Venkatanarayan A; Schaefer G; Dunlap D; Hoeck JD; Piskol R; Gnad F; Modrusan Z; de Sauvage FJ; Siebel CW; Jackson EL
Elife; 2019 May; 8():. PubMed ID: 31144617
[TBL] [Abstract][Full Text] [Related]
2. Interplay and cooperation between SREBF1 and master transcription factors regulate lipid metabolism and tumor-promoting pathways in squamous cancer.
Li LY; Yang Q; Jiang YY; Yang W; Jiang Y; Li X; Hazawa M; Zhou B; Huang GW; Xu XE; Gery S; Zhang Y; Ding LW; Ho AS; Zumsteg ZS; Wang MR; Fullwood MJ; Freedland SJ; Meltzer SJ; Xu LY; Li EM; Koeffler HP; Lin DC
Nat Commun; 2021 Jul; 12(1):4362. PubMed ID: 34272396
[TBL] [Abstract][Full Text] [Related]
3. Co-activation of super-enhancer-driven CCAT1 by TP63 and SOX2 promotes squamous cancer progression.
Jiang Y; Jiang YY; Xie JJ; Mayakonda A; Hazawa M; Chen L; Xiao JF; Li CQ; Huang ML; Ding LW; Sun QY; Xu L; Kanojia D; Jeitany M; Deng JW; Liao LD; Soukiasian HJ; Berman BP; Hao JJ; Xu LY; Li EM; Wang MR; Bi XG; Lin DC; Koeffler HP
Nat Commun; 2018 Sep; 9(1):3619. PubMed ID: 30190462
[TBL] [Abstract][Full Text] [Related]
4. ErbB activation signatures as potential biomarkers for anti-ErbB3 treatment in HNSCC.
Alvarado D; Ligon GF; Lillquist JS; Seibel SB; Wallweber G; Neumeister VM; Rimm DL; McMahon G; LaVallee TM
PLoS One; 2017; 12(7):e0181356. PubMed ID: 28723928
[TBL] [Abstract][Full Text] [Related]
5. ΔNp63α Suppresses TGFB2 Expression and RHOA Activity to Drive Cell Proliferation in Squamous Cell Carcinomas.
Abraham CG; Ludwig MP; Andrysik Z; Pandey A; Joshi M; Galbraith MD; Sullivan KD; Espinosa JM
Cell Rep; 2018 Sep; 24(12):3224-3236. PubMed ID: 30232004
[TBL] [Abstract][Full Text] [Related]
6. The Anti-HER3 mAb Seribantumab Effectively Inhibits Growth of Patient-Derived and Isogenic Cell Line and Xenograft Models with Oncogenic
Odintsov I; Lui AJW; Sisso WJ; Gladstone E; Liu Z; Delasos L; Kurth RI; Sisso EM; Vojnic M; Khodos I; Mattar MS; de Stanchina E; Leland SM; Ladanyi M; Somwar R
Clin Cancer Res; 2021 Jun; 27(11):3154-3166. PubMed ID: 33824166
[TBL] [Abstract][Full Text] [Related]
7. Neuregulin-1-mediated ErbB2-ErbB3 signalling protects human trophoblasts against apoptosis to preserve differentiation.
Fock V; Plessl K; Draxler P; Otti GR; Fiala C; Knöfler M; Pollheimer J
J Cell Sci; 2015 Dec; 128(23):4306-16. PubMed ID: 26490994
[TBL] [Abstract][Full Text] [Related]
8. Interplay between ΔNp63 and miR-138-5p regulates growth, metastasis and stemness of oral squamous cell carcinoma.
Zhuang Z; Xie N; Hu J; Yu P; Wang C; Hu X; Han X; Hou J; Huang H; Liu X
Oncotarget; 2017 Mar; 8(13):21954-21973. PubMed ID: 28423539
[TBL] [Abstract][Full Text] [Related]
9. TP63-Mediated Enhancer Reprogramming Drives the Squamous Subtype of Pancreatic Ductal Adenocarcinoma.
Somerville TDD; Xu Y; Miyabayashi K; Tiriac H; Cleary CR; Maia-Silva D; Milazzo JP; Tuveson DA; Vakoc CR
Cell Rep; 2018 Nov; 25(7):1741-1755.e7. PubMed ID: 30428345
[TBL] [Abstract][Full Text] [Related]
10. NRG1/ERBB3 Pathway Activation Induces Acquired Resistance to XPO1 Inhibitors.
Miyake TM; Pradeep S; Bayraktar E; Stur E; Handley KF; Wu SY; Rodriguez-Aguayo C; Lee JS; Lopez-Berestein G; Coleman RL; Sood AK
Mol Cancer Ther; 2020 Aug; 19(8):1727-1735. PubMed ID: 32499298
[TBL] [Abstract][Full Text] [Related]
11. Targeting the NRG1/HER3 pathway in tumor cells and cancer-associated fibroblasts with an anti-neuregulin 1 antibody inhibits tumor growth in pre-clinical models of pancreatic cancer.
Ogier C; Colombo PE; Bousquet C; Canterel-Thouennon L; Sicard P; Garambois V; Thomas G; Gaborit N; Jarlier M; Pirot N; Pugnière M; Vie N; Gongora C; Martineau P; Robert B; Pèlegrin A; Chardès T; Larbouret C
Cancer Lett; 2018 Sep; 432():227-236. PubMed ID: 29935372
[TBL] [Abstract][Full Text] [Related]
12. An ERBB3/ERBB2 oncogenic unit plays a key role in NRG1 signaling and melanoma cell growth and survival.
Zhang K; Wong P; Duan J; Jacobs B; Borden EC; Bedogni B
Pigment Cell Melanoma Res; 2013 May; 26(3):408-14. PubMed ID: 23480537
[TBL] [Abstract][Full Text] [Related]
13. ErbB3 Targeting Enhances the Effects of MEK Inhibitor in Wild-Type BRAF/NRAS Melanoma.
Capparelli C; Purwin TJ; Heilman SA; Chervoneva I; McCue PA; Berger AC; Davies MA; Gershenwald JE; Krepler C; Aplin AE
Cancer Res; 2018 Oct; 78(19):5680-5693. PubMed ID: 30115691
[TBL] [Abstract][Full Text] [Related]
14. Reciprocal inhibition between TP63 and STAT1 regulates anti-tumor immune response through interferon-γ signaling in squamous cancer.
Jiang Y; Zheng Y; Zhang YW; Kong S; Dong J; Wang F; Ziman B; Gery S; Hao JJ; Zhou D; Zhou J; Ho AS; Sinha UK; Chen J; Zhang S; Yin C; Wei DD; Hazawa M; Pan H; Lu Z; Wei WQ; Wang MR; Koeffler HP; Lin DC; Jiang YY
Nat Commun; 2024 Mar; 15(1):2484. PubMed ID: 38509096
[TBL] [Abstract][Full Text] [Related]
15. TRP63/TP63 loss accelerates skin tumorigenesis through activation of Wnt/β-catenin signaling.
Lakshmanachetty S; Balaiya V; Johnson LK; Koster MI
J Dermatol Sci; 2018 Sep; 91(3):325-328. PubMed ID: 29885760
[No Abstract] [Full Text] [Related]
16. miR-296-5p suppresses EMT of hepatocellular carcinoma via attenuating NRG1/ERBB2/ERBB3 signaling.
Shi DM; Li LX; Bian XY; Shi XJ; Lu LL; Zhou HX; Pan TJ; Zhou J; Fan J; Wu WZ
J Exp Clin Cancer Res; 2018 Nov; 37(1):294. PubMed ID: 30486894
[TBL] [Abstract][Full Text] [Related]
17. The neuregulin-I/ErbB signaling system in development and disease.
Britsch S
Adv Anat Embryol Cell Biol; 2007; 190():1-65. PubMed ID: 17432114
[TBL] [Abstract][Full Text] [Related]
18. Neuregulin-1 induces cancer stem cell characteristics in breast cancer cell lines.
Jeong H; Kim J; Lee Y; Seo JH; Hong SR; Kim A
Oncol Rep; 2014 Sep; 32(3):1218-24. PubMed ID: 25018110
[TBL] [Abstract][Full Text] [Related]
19. Constitutive activation of neuregulin/ERBB3 signaling pathway in clear cell sarcoma of soft tissue.
Schaefer KL; Brachwitz K; Braun Y; Diallo R; Wai DH; Zahn S; Schneider DT; Kuhnen C; Vollmann A; Brockhoff G; Gabbert HE; Poremba C
Neoplasia; 2006 Jul; 8(7):613-22. PubMed ID: 16867224
[TBL] [Abstract][Full Text] [Related]
20. Neuregulin 1 expression is a predictive biomarker for response to AV-203, an ERBB3 inhibitory antibody, in human tumor models.
Meetze K; Vincent S; Tyler S; Mazsa EK; Delpero AR; Bottega S; McIntosh D; Nicoletti R; Winston WM; Weiler S; Feng B; Gyuris J; Weng Z
Clin Cancer Res; 2015 Mar; 21(5):1106-14. PubMed ID: 25542901
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
